Severin Ruoss

Jul 12, 2024 | science.org | Caterina Montani |Hui Ye |ZhiJun Qiu |Severin Ruoss |Chanond A. Nasamran |Scott Ball | +11 more

AbstractBone marrow aspirate concentrate (BMAC) and adipose-derived stromal vascular fraction (ADSVF) are the most marketed stem cell therapies to treat a variety of conditions in the general population and elite athletes. Both tissues have been used interchangeably clinically even though their detailed composition, heterogeneity, and mechanisms of action have neither been rigorously inventoried nor compared.